The Experts below are selected from a list of 309 Experts worldwide ranked by ideXlab platform
Hiroyuki Hamakawa - One of the best experts on this subject based on the ideXlab platform.
-
Carrier Cell‐mediated Cell lysis of Squamous Cell carcinoma Cells by Squamous Cell carcinoma antigen 1 promoter‐driven oncolytic adenovirus
The journal of gene medicine, 2010Co-Authors: Katsuyuki Hamada, Hiroshi Itoh, Kenzaburo Tani, Ting Zhang, Junzo Desaki, Koh-ichi Nakashiro, Yoshiyuki Koyama, Hiroyuki HamakawaAbstract:Background The Squamous Cell carcinoma antigen (SCCA) serves as a serological marker for Squamous Cell carcinomas. Molecular cloning of the SCCA genomic region has revealed the presence of two tandemly arrayed genes: SCCA1 and SCCA2. SCCA1 gene is up-regulated in Squamous Cell carcinoma Cells. We analyzed the proximal region of the SCCA1 promoter and the antitumor effect of oncolytic adenovirus driven by the SCCA1 promoter in Squamous Cell carcinoma Cells. Methods The SCCA1 promoter was analyzed by dual luciferase assay and substituted with the E1A promoter to construct the oncolytic adenovirus to determine the Squamous Cell carcinoma-specific Cell lysis. Results Deletion analysis of SCCA1 promoter identified a 175-bp core promoter region and an enhancer region at −525 to −475 bp upstream of the transcription start site. The transcriptional activity of the SCCA1 promoter was up-regulated in Squamous Cell carcinoma Cells. Five tandem repeats of enhancer increased SCCA1 promoter activity by four-fold. Oncolytic adenovirus driven by this SCCA1 enhancer-promoter complex specifically killed Squamous Cell carcinoma Cells in vitro and in vivo. A549 carrier Cells infected with the oncolytic adenovirus induced complete regression of syngeneic Squamous Cell carcinoma Cell tumor by overcoming immunogenicity and adenovirus-mGM-CSF augmented the antitumor effect of carrier Cells. Conclusions SCCA1 was up-regulated in Squamous Cell carcinoma Cells and oncolytic adenovirus driven by SCCA1 promoter specifically killed these Cells. These findings suggest that SCCA1 promoter is a potential target of gene therapy for Squamous Cell carcinoma. Copyright © 2010 John Wiley & Sons, Ltd.
-
Carrier Cell-mediated Cell lysis of Squamous Cell carcinoma by Squamous Cell carcinoma antigen 1 promoter-driven oncolytic adenovirus
Nature Precedings, 2009Co-Authors: Katsuyuki Hamada, Kenzaburo Tani, Ting Zhang, Junzo Desaki, Koh-ichi Nakashiro, Yoshiyuki Koyama, Hiroshi Ito, Hiroyuki HamakawaAbstract:The Squamous Cell carcinoma antigen (SCCA) serves as a serological marker for Squamous Cell carcinomas. Molecular cloning of the SCCA genomic region has revealed the presence of two tandemly arrayed genes, SCCA1 and SCCA2. We examined the promoter activity of the 5'-flanking proximal region of the SCCA1 gene. Deletion analysis of SCCA1 promoter identified a 175-bp core promoter region and an enhancer region at -525 to -475 bp upstream of the transcription start site. The transcriptional activity of the SCCA1 promoter was up-regulated in Squamous Cell carcinoma Cells, compared with normal keratinocyte, normal non-keratinocyte and adenocarcinoma Cells. Five tandem repeats of enhancer increased SCCA1 promoter activity by 4-fold. Oncolytic adenovirus driven by the SCCA1 promoter with 5 tandem repeats of enhancer specifically killed Squamous Cell carcinoma Cells in vitro and in vivo. A549 carrier Cells infected with the oncolytic adenovirus induced complete regression of tumor by overcoming immunogenicity and adenovirus-mGM-CSF augmented the antitumor effect of carrier Cells. These findings suggest that SCCA1 promoter is a potential target of gene therapy for Squamous Cell carcinoma.
Yuan Chen - One of the best experts on this subject based on the ideXlab platform.
-
Meta-analysis comparing the efficacy of nedaplatin-based regimens between Squamous Cell and non-Squamous Cell lung cancers.
Oncotarget, 2017Co-Authors: Yijun Tian, Qian Liu, Qian Chu, Yuan ChenAbstract:Non-small Cell lung cancer (NSCLC) consists of several subtypes, including adenocarcinoma, Squamous Cell lung cancer, large Cell lung cancer, and other rarer types. Platinum-based regimens are currently the standard for treatment of advanced NSCLC. Nedaplatin is reportedly associated with a high response rate in Squamous Cell lung cancer. However, the relevant studies are small and mainly descriptive. The purpose of this meta-analysis was therefore to compare the efficacy of nedaplatin in Squamous Cell lung cancer with that in non-Squamous Cell lung cancer. Studies concerning nedaplatin-based regimens in NSCLC patients were retrieved from PubMed and EMBASE. The response rate for nedaplatin-based regimens in Squamous Cell lung cancer (ORR: 55.6%, 95% CI: 52.5-58.7%) was higher (OR: 1.55, 95% CI: 1.17-2.05) than that for non-Squamous Cell lung cancer (ORR: 34.4%, 95% CI: 32.3-36.5%). In addition, Taxane plus nedaplatin produced a longer overall and progress-free survival than CPT-11 or gemcitabine plus nedaplatin. To verify these findings, future well-controlled clinical studies will be needed.
Katsuyuki Hamada - One of the best experts on this subject based on the ideXlab platform.
-
Carrier Cell‐mediated Cell lysis of Squamous Cell carcinoma Cells by Squamous Cell carcinoma antigen 1 promoter‐driven oncolytic adenovirus
The journal of gene medicine, 2010Co-Authors: Katsuyuki Hamada, Hiroshi Itoh, Kenzaburo Tani, Ting Zhang, Junzo Desaki, Koh-ichi Nakashiro, Yoshiyuki Koyama, Hiroyuki HamakawaAbstract:Background The Squamous Cell carcinoma antigen (SCCA) serves as a serological marker for Squamous Cell carcinomas. Molecular cloning of the SCCA genomic region has revealed the presence of two tandemly arrayed genes: SCCA1 and SCCA2. SCCA1 gene is up-regulated in Squamous Cell carcinoma Cells. We analyzed the proximal region of the SCCA1 promoter and the antitumor effect of oncolytic adenovirus driven by the SCCA1 promoter in Squamous Cell carcinoma Cells. Methods The SCCA1 promoter was analyzed by dual luciferase assay and substituted with the E1A promoter to construct the oncolytic adenovirus to determine the Squamous Cell carcinoma-specific Cell lysis. Results Deletion analysis of SCCA1 promoter identified a 175-bp core promoter region and an enhancer region at −525 to −475 bp upstream of the transcription start site. The transcriptional activity of the SCCA1 promoter was up-regulated in Squamous Cell carcinoma Cells. Five tandem repeats of enhancer increased SCCA1 promoter activity by four-fold. Oncolytic adenovirus driven by this SCCA1 enhancer-promoter complex specifically killed Squamous Cell carcinoma Cells in vitro and in vivo. A549 carrier Cells infected with the oncolytic adenovirus induced complete regression of syngeneic Squamous Cell carcinoma Cell tumor by overcoming immunogenicity and adenovirus-mGM-CSF augmented the antitumor effect of carrier Cells. Conclusions SCCA1 was up-regulated in Squamous Cell carcinoma Cells and oncolytic adenovirus driven by SCCA1 promoter specifically killed these Cells. These findings suggest that SCCA1 promoter is a potential target of gene therapy for Squamous Cell carcinoma. Copyright © 2010 John Wiley & Sons, Ltd.
-
Carrier Cell-mediated Cell lysis of Squamous Cell carcinoma by Squamous Cell carcinoma antigen 1 promoter-driven oncolytic adenovirus
Nature Precedings, 2009Co-Authors: Katsuyuki Hamada, Kenzaburo Tani, Ting Zhang, Junzo Desaki, Koh-ichi Nakashiro, Yoshiyuki Koyama, Hiroshi Ito, Hiroyuki HamakawaAbstract:The Squamous Cell carcinoma antigen (SCCA) serves as a serological marker for Squamous Cell carcinomas. Molecular cloning of the SCCA genomic region has revealed the presence of two tandemly arrayed genes, SCCA1 and SCCA2. We examined the promoter activity of the 5'-flanking proximal region of the SCCA1 gene. Deletion analysis of SCCA1 promoter identified a 175-bp core promoter region and an enhancer region at -525 to -475 bp upstream of the transcription start site. The transcriptional activity of the SCCA1 promoter was up-regulated in Squamous Cell carcinoma Cells, compared with normal keratinocyte, normal non-keratinocyte and adenocarcinoma Cells. Five tandem repeats of enhancer increased SCCA1 promoter activity by 4-fold. Oncolytic adenovirus driven by the SCCA1 promoter with 5 tandem repeats of enhancer specifically killed Squamous Cell carcinoma Cells in vitro and in vivo. A549 carrier Cells infected with the oncolytic adenovirus induced complete regression of tumor by overcoming immunogenicity and adenovirus-mGM-CSF augmented the antitumor effect of carrier Cells. These findings suggest that SCCA1 promoter is a potential target of gene therapy for Squamous Cell carcinoma.
Yijun Tian - One of the best experts on this subject based on the ideXlab platform.
-
Meta-analysis comparing the efficacy of nedaplatin-based regimens between Squamous Cell and non-Squamous Cell lung cancers.
Oncotarget, 2017Co-Authors: Yijun Tian, Qian Liu, Qian Chu, Yuan ChenAbstract:Non-small Cell lung cancer (NSCLC) consists of several subtypes, including adenocarcinoma, Squamous Cell lung cancer, large Cell lung cancer, and other rarer types. Platinum-based regimens are currently the standard for treatment of advanced NSCLC. Nedaplatin is reportedly associated with a high response rate in Squamous Cell lung cancer. However, the relevant studies are small and mainly descriptive. The purpose of this meta-analysis was therefore to compare the efficacy of nedaplatin in Squamous Cell lung cancer with that in non-Squamous Cell lung cancer. Studies concerning nedaplatin-based regimens in NSCLC patients were retrieved from PubMed and EMBASE. The response rate for nedaplatin-based regimens in Squamous Cell lung cancer (ORR: 55.6%, 95% CI: 52.5-58.7%) was higher (OR: 1.55, 95% CI: 1.17-2.05) than that for non-Squamous Cell lung cancer (ORR: 34.4%, 95% CI: 32.3-36.5%). In addition, Taxane plus nedaplatin produced a longer overall and progress-free survival than CPT-11 or gemcitabine plus nedaplatin. To verify these findings, future well-controlled clinical studies will be needed.
Stephen L. Rose - One of the best experts on this subject based on the ideXlab platform.
-
Subungual Squamous Cell carcinoma of the finger.
AJR. American journal of roentgenology, 2005Co-Authors: Liem T. Bui-mansfield, Joseph P. Pulcini, Stephen L. RoseAbstract:5Department of Surgery, Orthopedic Service, Brooke Army Medical Center, San Antonio, TX 78234. 53-year-old woman presented to a dermatologist with a subungual mass in the right index finger. Radiographs revealed a subungual soft-tissue mass that had eroded into the distal phalanx of the index finger. The dermatologist performed a biopsy, revealing the diagnosis of Squamous Cell carcinoma. The index finger was amputated. The differential diagnosis of an erosive lesion in the distal phalanx includes implantation dermoid cyst, subungual fibroma, glomus tumor, giant Cell tumor of tendon sheath, subungual Squamous Cell carcinoma, subungual keratoacanthoma, and mucous cyst [1]. Radiologically, subungual Squamous Cell carcinoma is almost indistinguishable from subungual keratoacanthoma. Keratoacanthoma is a localized endoexophytic growth of Squamous epithelium with a characteristic central keratin-filled crater. Keratoacanthomas may be locally destructive and sometimes are associated with transformation to Squamous Cell carcinoma with subsequent invasion. Some authors consider keratoacanthoma a subset of Squamous Cell carcinoma [2]; however, keratoacanthomas more frequently undergo spontaneous involution, and the larger consensus is that they are separate lesions with distinctive behavior. The treatment of subungual keratoacanthoma is conservative, while that of subungual Squamous Cell carcinoma is amputation. Both subungual keratoacanthoma and Squamous Cell carcinoma may present with pain, localized swelling, and inflammation. Patients with subungual Squamous Cell carcinoma tend to be older (seventh decade peak) than those with keratoacanthoma (fifth decade peak) [1–4]. Squamous Cell carcinoma grows slowly and often is mistaken for chronic inflammation. In contrast, subungual keratoacanthoma grows rapidly, proliferating to an obvious 1to 2-cm mass within several weeks to months; then generally stabilizes and later spontaneously involutes, leaving a small pitted scar [1]. Eighty-four percent of subungual Squamous Cell carcinomas occur in the fingers, the remaining in the toes. The majority of subungual Squamous Cell carcinoma in the fingers occurs in the thumb (44%); and those in the toes affect the great toe predominately (64%) [3, 4]. Predisposing factors for subungual Squamous Cell carcinoma include chronic paronychia, trauma, congenital ectodermal dysplasia, radiation exposure, and previous human papillomavirus (HPV) infection [3, 4]. In A
